News

Patient Capital Management Q1 2025 Commentary
The first quarter was a punch in the face, though not a pummeling—that’s what started in the second quarter. Click here to ...
3 clues about what's next for the S&P 500 after weeks of tariff-fueled selling
"The message from price action can be much more transparent than what you may read about in the financial press or see on ...
Dow Jones: Value Stocks Do Not Provide a Safe-Haven Refuge
Nasdaq 100, S&P 500, Dow Jones Industrial Average, Dow Jones Futures. Read 's Market Analysis on Investing.com ...
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...
GigaCloud Technology: Quantifying The Impact Of China Tariffs
GigaCloud Technology's stock fell nearly 50%, significantly underperforming the S&P 500. Click here to find out why GCT stock ...
The weakness in the 3 major Dow Jones indexes is unanimous
As an example of how broad the selling is, all the of the components of the three major Dow Jones indexes are seeing red. The 30 components of the Dow Jones Industrial Average are all trading lower, ...